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OBJECTIVES The purpose of this study was to compare transvenous atrial defibrillation thresholds with lead
configurations consisting of an active left pectoral electrode and either single or dual
transvenous coils.
BACKGROUND Low atrial defibrillation thresholds are achieved using complex lead systems including coils in
the coronary sinus. However, the efficacy of more simple ventricular defibrillation leads with
active pectoral pulse generators to defibrillate atrial fibrillation (AF) is unknown.
METHODS This study was a prospective, randomized assessment of shock configuration on atrial
defibrillation thresholds in 32 patients. The lead system was a dual coil Endotak DSP lead
with a left pectoral pulse generator emulator. Shocks were delivered either between the right
ventricular coil and an active can in common with the proximal atrial coil (triad) or between
the atrial coil and active can (transatrial).
RESULTS Delivered energy at defibrillation threshold was 7.1 6 6.0 J in the transatrial configuration
and 4.0 6 4.2 J in the triad configuration (p , 0.005). Moreover, a low threshold (#3 J) was
observed in 69% of subjects in the triad configuration but only 47% in the transatrial
configuration. Peak voltage and shock impedance were also lowered significantly in the triad
configuration. Left atrial size was the only clinical predictor of the defibrillation theshold (r 5
0.57, p , 0.002).
CONCLUSIONS These results indicate that low atrial defibrillation thresholds can be achieved using a
single-pass transvenous ventricular defibrillation lead with a conventional ventricular defi-
brillation pathway. These data support the development of the combined atrial and
ventricular defibrillator system. (J Am Coll Cardiol 1999;34:358–62) © 1999 by the
American College of Cardiology
The implantable cardioverter defibrillator (ICD) is now
primary therapy for many patients with life-threatening
ventricular arrhythmias (1–3). Clinically significant atrial
fibrillation (AF) is frequently observed in patients with
ICDs; indirect data suggest an incidence of at least 20%,
although the exact figure is unknown and may be higher (4).
The presence of AF in general is associated with an
increased incidence of thromboembolic events including
stroke, adverse effects on cardiac function and increased
mortality (5–7). In addition, many patients are severely
symptomatic even if the AF is not hemodynamically com-
promising (8).
An implantable atrial defibrillator is currently undergoing
clinical evaluation (9). On the basis of experimental and
clinical studies, low atrial defibrillation thresholds have been
demonstrated using complex lead systems including coils in
the coronary sinus (10–12). Given the high incidence of AF
in patients with ICDs, the possibility of using these devices
for atrial defibrillation is intriguing. Because standard active
pectoral ICD lead systems deliver current with a vector
through the heart including the atria, we postulated that an
active pectoral, single-pass lead would be an effective means
to achieve atrial defibrillation, and further, that the efficacy
of this system would be dependent on the shocking path-
way. Accordingly, the present study was a prospective
randomized evaluation of active can lead configuration on
atrial defibrillation thresholds in patients undergoing ICD
implantation. In addition to measuring the efficacy of atrial
defibrillation, the clinical predictors of a low defibrillation
threshold were assessed.
METHODS
Patient group. Thirty-four consecutive patients undergo-
ing initial ICD implant for standard indications were
evaluated. By protocol, all patients were in sinus rhythm at
the time of implant, and all implants were left-sided.
Written informed consent was obtained from each patient,
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Defibrillation lead system implantation. Each patient
received an Endotak DSP defibrillation lead (Model 0125),
which was positioned at the right ventricular apex under
fluoroscopic guidance via either the left cephalic, axillary or
subclavian vein. This lead consists of two defibrillating coils,
a proximal coil at the right atrial/superior vena caval
junction and a second distal coil in the right ventricle. In
patients undergoing dual-chamber ICD implant, a separate
active fixation atrial lead (Model 4269) was placed in the
right atrium. In the remaining patients, a temporary quad-
ripolar pacing catheter was advanced (using the same venous
access as the ICD lead) to the lateral right atrium for
induction of AF. For acute defibrillation testing, a pulse
generator emulator (Model 6967) with a surface area of
78.4 cm2 was placed in the left subcutaneous prepectoral
pocket. All implanted lead components were manufactured
by Cardiac Pacemakers Inc. (Guidant, St. Paul, Minnesota).
Atrial defibrillation testing. Measurement of the atrial
defibrillation threshold was performed under conscious
sedation with midazolam and fentanyl. Atrial fibrillation
was induced with either high output ramp pacing or with
alternating current stimulation. When AF had been sus-
tained for .1 min, defibrillation testing was performed.
The R-wave synchronized defibrillation shocks were deliv-
ered with an external defibrillator (ECD Model 2815,
Cardiac Pacemakers), which delivers fixed 60/50 tilt bipha-
sic shocks through a 125 mF capacitance. A step-up proto-
col was employed, starting at 0.5 J and increasing (1, 2, 3, 5,
8, 10, 15, 20 J) until there was restoration of sinus rhythm.
The atrial defibrillation threshold was defined as the lowest
energy shock to terminate atrial fibrillation. A threshold
#3 J was defined prospectively as low energy to allow
comparison with reduced output atrial defibrillators (9).
Two different shocking pathways were evaluated in each
patient, with the order of testing randomized (Fig. 1). In the
triad configuration, the distal right ventricular coil is the
anode for the first phase of the biphasic shocks and the
proximal right atrial coil and emulator are connected elec-
trically as the cathode (13). The second shocking pathway
was the transatrial configuration in which the proximal coil
is the anode and the emulator is the cathode. The right
ventricular coil was excluded from the system in this
configuration.
Data analysis. The following variables were analyzed as
possible predictors of atrial defibrillation threshold: age,
gender, body surface area, past history of AF, amiodarone
use in the previous three months, left ventricular ejection
fraction and left atrial size as assessed by echocardiography.
The relationships between continuous variables and atrial
defibrillation threshold were assessed by linear regression
using a least-squares algorithm. For discrete variables,
unpaired t tests were performed. Multivariate analysis was
then done on all variables with p , 0.10 by stepwise
multiple logistic regression with the triad atrial defibrillation
threshold as the dependent variable (StatMost 3.5, Data-
Most, Salt Lake City, Utah).
Analysis of the clinical characteristics of subjects with
high atrial defibrillation thresholds was also performed.
Patients were grouped by the prospectively defined cutoff of
3 J. Comparison of the high and low threshold groups were
made using unpaired t tests for continuous variables and the
Fisher exact test for discrete variables. Electrical parameters
between the two lead configurations were compared using
paired t tests. All data are presented as mean 6 SD, and a
p value ,0.05 was considered significant.
RESULTS
Patient population. There were 34 consecutive patients
enrolled in this study, and sustained AF could be induced in
32 of them who formed the study group. The subjects were
81% male with a mean age of 65 6 10 years and a mean
ejection fraction of 0.30 6 0.14. Coronary artery disease
with ischemic cardiomyopathy was the primary structural
Abbreviations and Acronyms
AF 5 atrial fibrillation
ICD 5 implantable cardioverter defibrillator
Figure 1. A schematic representation of the defibrillation shocking
pathways. The dual-coil transvenous lead is positioned so that the
tip is in the right ventricular apex. (A) The triad configuration is
shown in which the distal coil in the right ventricle serves as the
anode (1) for defibrillation. The pectoral can is connected elec-
trically to the proximal atrial coil and serves as the cathode (2). (B)
The transatrial configuration is shown in which the can alone
serves as the cathode with the proximal coil as the anode.
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heart disease in 28 patients, 1 had idiopathic dilated
cardiomyopathy and 3 patients had primary electrical dis-
ease with no known structural heart disease. At the time of
implantation, 6 patients (19%) were receiving amiodarone.
No patients were receiving other type I or type III antiar-
rhythmic drug therapy.
Atrial defibrillation. All patients tolerated the induction
and termination of AF without complications. Specifically,
there were no embolic events or ventricular arrhythmias
induced with atrial defibrillation testing. Moreover, all
patients were amnestic to the shocks following implanta-
tion. A mean of 8.9 6 3.9 atrial defibrillation shocks were
delivered per patient.
A summary of the electrical parameters measured at the
atrial defibrillation threshold for the two shocking pathways
is shown in Table 1. Atrial defibrillation energy require-
ments were reduced from 7.1 6 6.0 J in the transatrial
configuration to 4.0 6 4.2 J in the triad configuration (p ,
0.005). Thus, by delivering shocks between the ventricular
coil and the atrial coil connected to the emulator, there was
a 44% reduction of defibrillation thresholds compared with
the shocking pathway between the right atrium and left
pectoral emulator (Fig. 1).
Peak voltage at the atrial defibrillation threshold was
reduced 26% in the triad configuration (p , 0.005). As
expected, the shock impedance was also lowered signifi-
cantly (18%) with the three-electrode, dual-coil triad con-
figuration compared with the two-electrode, single-coil
transatrial configuration. However, peak current did not
differ significantly between the two configurations. This
indicates that the reduction of impedance in the triad
configuration is sufficient to account for the lowering of
defibrillation threshold voltage and energy (13).
Histograms of the distributions of atrial defibrillation
thresholds are shown in Figure 2. We prospectively defined
defibrillation with #3 J as a low threshold, because this is
the approximate energy requirement needed to implant a
stand-alone atrial defibrillator with limited output capability
(9). Low-energy thresholds were achieved in 69% (22 of 32)
of subjects in the triad configuration, but only 47% (15 of
32) in the transatrial configuration (p 5 0.06). The triad
and optimal atrial defibrillation threshold histograms are
very similar. In fact, the transatrial defibrillation threshold
was more than 1 J lower than the triad threshold in only 3
patients (9%), whereas the triad defibrillation threshold was
more than 1 J lower than the transatrial in 17 patients (53%,
p , 0.01). This suggests that the ability to program the
shocking pathway in this patient population would offer
little benefit.
The clinical characteristics of the patient population
are shown in Table 2. The patients are grouped by the
triad defibrillation threshold. Of the seven clinical vari-
ables assessed, only left atrial size differed significantly
between the groups with high and low thresholds. Sim-
ilarly, multivariate analysis, with left atrial size and age as
independent variables (see Methods section), identified
left atrial size as the only independent predictor of the
triad atrial defibrillation threshold. A scatter plot of the
relationship between defibrillation threshold and left
atrial size is shown in Figure 3.





Energy (J) 4.0 6 4.2 7.1 6 6.0 0.002
Voltage (V) 204 6 102 275 6 133 0.004
Current (A) 4.7 6 2.6 5.4 6 3.0 0.194
Impedance (V) 45 6 6 55 6 12 , 0.001
Figure 2. Distribution of atrial defibrillation thresholds. Histo-
grams of atrial defibrillation thresholds (ADFT) are shown for the
triad (top panel), transatrial (middle panel) and optimal (bottom
panel) configurations. The optimal configuration was the config-
uration with the lower of the two defibrillation thresholds in the
patient.
Table 2. Comparison of Clinical Parameters of the High and






Gender (% male) 86 70
Age (yrs) 67 6 9 60 6 10
Body surface area (m2) 1.94 6 0.19 1.99 6 0.19
History of AF (%) 41 50
Amiodarone use (%) 14 30
Ejection fraction 0.30 6 0.13 0.31 6 0.17
LA size (cm) 4.1 6 0.7 4.8 6 0.7*
*p , 0.05.
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DISCUSSION
The major finding of this study was the high efficacy of a
single-pass, dual-coil transvenous ventricular defibrillator
lead to terminate induced AF. Defibrillation energy require-
ments were lower in the triad configuration compared with
the transatrial configuration. Only left atrial size, among
those clinical parameters evaluated, showed a significant
correlation with the atrial defibrillation threshold.
Comparison with previous studies. Internal cardioversion
of atrial defibrillation was first reported nearly 30 years ago,
and since then, several animal and human studies have
confirmed the ability of transvenous shocks to defibrillate
AF (10–12,14,15). The shocking lead configuration, and
more recently the defibrillation waveform, have been shown
to be important determinants of defibrillation thresholds
(16,17). In general, the lowest thresholds are observed with
complex lead systems including defibrillation coils in the
coronary sinus, although these thresholds are not sufficiently
low to prevent pain in nonsedated subjects. Moreover, the
long-term safety and ability to extract these leads because of
infection or malfunction are unknown. Consequently, a
simple single lead that is easy to implant should be advan-
tageous for chronic systems.
There are limited data on the ability of standard ventric-
ular defibrillator lead systems to defibrillate AF. We previ-
ously showed that properly timed low-energy shocks could
induce AF, but defibrillation required shock energies $3 J
(18). Two lead systems were evaluated in that study, a right
atrial coil and left ventricular patch configuration and a
dual-coil transvenous lead. The relationship between the
induction and termination of atrial fibrillation was consis-
tent with the upper limit of vulnerability hypothesis, sug-
gesting that the use of low-energy shocks in sinus rhythm to
induce AF may be useful to predict atrial defibrillation
thresholds. However, atrial defibrillation thresholds were
not evaluated systematically in that study. Both human and
animal studies have demonstrated the ability to achieve
atrial defibrillation with a dual-coil transvenous lead
(19,20).
Ventricular proarrhythmia. The potential for atrial defi-
brillation shocks to induce ventricular fibrillation remains a
major concern (20–22), although to date this has not been
reported in clinical trials with the atrial defibrillator. How-
ever, reduced output atrial defibrillators have only under-
gone evaluation in patients without structural heart disease,
because backup ventricular defibrillation capabilities are not
present in these devices. It is noteworthy, therefore, that no
ventricular arrhythmias were induced with atrial defibrilla-
tion testing in the present study in which all but three
patients had a reduced ejection fraction. Although the
induction of ventricular arrhythmias is still undesirable with
atrial defibrillation shocks, the consequences are likely less
severe with ICD systems capable of ventricular defibrilla-
tion.
Clinical predictors of defibrillation threshold. Left atrial
size was the only clinical predictor of a high atrial defibril-
lation threshold. This is analogous to clinical predictors of
ventricular defibrillation thresholds, in which left ventricular
size or mass has been shown to predict high biphasic
thresholds (23,24). Studies of transthoracic atrial defibrilla-
tion have identified left atrial size and duration of AF as
predictors of high thresholds or unsuccessful cases (25,26).
The duration of AF is not a factor for defibrillation with
implantable systems because shocks are delivered acutely
after the onset of the arrhythmia.
Study limitations. Our study must be interpreted in the
face of certain methodologic limitations. First, defibrillation
thresholds of induced, but not spontaneous, AF were
measured. Therefore, it is possible that the lead configura-
tions tested would have a lower efficacy for the termination
of spontaneous AF. However, previous studies have shown
that defibrillation thresholds of induced AF are similar to
spontaneous AF (27,28). Moreover, at least 1 min of AF
was required before testing was begun, thus minimizing the
chance that AF terminated spontaneously rather than by the
delivered shock. Second, atrial defibrillation thresholds were
measured in two configurations, so it is possible that the
optimal shocking pathway for atrial defibrillation with this
single-pass lead was not identified. Finally, only a single
biphasic waveform was evaluated. Recently, it was shown
that a large capacitance waveform markedly reduced thresh-
olds (29). Therefore, it is possible that lower thresholds
could be obtained with other waveforms or capacitances and
this lead system.
Conclusions. This study demonstrated low atrial defibril-
lation thresholds using a single-pass transvenous ventricular
defibrillation lead with a conventional ventricular defibril-
lation pathway. Given the simplicity of implantation and
chronic stability of integrated ventricular defibrillation leads,
this single-lead, active pectoral configuration should be
considered as an alternative to the more complex multiple-
Figure 3. The relationship between left atrial size and atrial
defibrillation theshold. A scatter plot is presented. The line is the
linear regression fit of the data.
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lead systems now in clinical trials. These data support the
development of the combined atrial and ventricular ICD
system, although further studies are needed to identify
optimal defibrillation pathways and waveforms.
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